Double attack on deadly pancreatic cancer shows promise
NCT ID NCT07176702
Summary
This study is testing whether adding a new antibody called HLX22 to an existing treatment (trastuzumab plus chemotherapy) works better for people with a specific type of advanced pancreatic cancer (HER2-positive). It aims to see if this combination can shrink tumors and help patients live longer. The trial is for adults with newly diagnosed metastatic pancreatic cancer who have not had prior treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Nanjing, 210008, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200233, China
Conditions
Explore the condition pages connected to this study.